Clinical trial averages suggest 48 pounds monthly initially, but your actual results depend on genetics, starting weight, and lifestyle
General wellness enthusiasts : Anyone looking to support bone health, energy production, or overall well-being can benefit
Abstract Introduction Clinical trials have demonstrated greater glycemic control and weight loss with once-weekly (OW) semaglutide versus other anti-diabetes medications, including sodium-glucose co-transporter 2 inhibitors (SGLT2is) in adults with type 2 diabetes (T2D), yet real-world evidence is limited
The booming class of GLP-1 drugs that includes Ozempic and Wegovy is not only effective for diabetes and obesity, but is also showing early potential to help with conditions involving the brain, like mental health disorders, Alzheimers, and even, as new study results suggest Parkinsons disease
It might be safe to use GLP-1 [receptor agonists] in the preoperative period, Qais AbuHasan , MD, research fellow at the Indiana University School of Medicine, who presented the findings, said in the release